Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced that it will report its first-quarter 2026 operating and financial results via press release on May 15. The update will include financial results for the quarter ended March 31, 2026, along with operational updates regarding the company's clinical trials and development of its proprietary artificial intelligence and machine learning platforms.
The company's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
Lantern's multi-agentic AI co-scientist platform, withZeta.ai, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
This announcement matters because it provides investors and the industry with insights into Lantern's financial health and progress in its clinical trials. The company's use of AI and machine learning to accelerate drug development could potentially transform cancer therapy development, making it more efficient and cost-effective. The commercial launch of withZeta.ai also opens a new revenue stream and offers broader access to AI-driven drug discovery tools for the biomedical community.
The full press release is available at https://ibn.fm/dVleQ. For more information about Lantern Pharma, visit their newsroom at https://ibn.fm/LTRN.
